9th International mRNA Health Conference


November 09 - 10, 2021

Currently planned as hybrid event on-site in Berlin, Germany, and online via virtual platform.
Reigster now and join us at the conference!

Nothing found.


Past Events & Presentations

Final Analysis of Phase 2b/3 Clinical Trial for CVnCoV – Webcast & Conference Call


July 1, 2021

On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a conference call and webcast on Thursday, July 1, 2021, 2:00 p.m. CET / 8:00 a.m. EDT.

A replay of the webcast can be found under "Links".

Final Analysis of Phase 2b/3 Clinical Trial of CVnCoV – Press Conference in German Language


July 01, 2021

On Wednesday, June 30, 2021, CureVac N.V. (Nasdaq: CVAC) announced results from the final analysis of its 40,000 subject international pivotal Phase 2b/3 study (the HERALD study) of the first-generation COVID-19 vaccine candidate, CVnCoV.

The company hosted a press conference in German language on Thursday, July 1, 2021, 10:00 a.m. CEST.

The corresponding presentation slides can be found under "Downloads". An replay of the press conference can be found under "Links".

Downloads

Links

Annual General Meeting 2021


June 24, 2021

The Annual General Meeting (the “AGM”) of Shareholders of CureVac N.V. was held on Thursday, June 24, 2021, at 2:00 p.m. Central European Summer Time. The AGM was held entirely virtually, without physical attendance of shareholders or others with meeting rights. You were not be able to vote during the AGM and your proxy to vote had to be received no later than 5:59 a.m. Central European Summer Time on Tuesday, June 22, 2021.

More Information

Update on Phase 2b/3 Clinical Trial for CureVac’s First-Generation COVID-19 Vaccine candidate, CVnCoV – Webcast & Conference Call


June 17, 2021

To provide an update on Phase 2b/3 clinical trial for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, CureVac N.V. (Nasdaq: CVAC) hosted a webcast and conference call on Thursday, June 17, 2021, at 2:00 p.m. CEST / 8:00 a.m. EST.

The corresponding press release, presentation slides and transcript can be found under “Downloads”. An archived webcast can be found under "Links".

German Hauptstadtkongress Medizin und Gesundheit 2021


June 16, 2021

Virtual Panel Discussion (German only):
Medizinischer Fortschritt „Made in Germany“: Gewollt, ermöglicht und erreichbar?

STING & TLR-Targeting Therapies Summit Digital


May 25 - 27, 2021

Virtual Event

Berenberg Conference USA 2021


May 18 - 20, 2021

Virtual Event

Kempen Life Sciences Conference 2021


April 28, 2021

Virtual Event

Fourth Quarter and Full-Year 2020 Financial Results and Business Updates – Conference Call & Webcast


April 15, 2021

CureVac N.V. (Nasdaq: CVAC) reported financial results and business updates for the fourth quarter and full-year of 2020 on Thursday, April 15, 2021, at 4:00 p.m. CET / 10:00 a.m. EST.

Please find the corresponding press release, presentation slides, transcript as well as the archived webcast below.

Credit Suisse 2021 London Global Healthcare Conference


March 2, 2021

Virtual Event
Fireside Chat: 12:00 p.m. GMT / 7:00 a.m. EST